News
News About Marathon and Its Investments
-
AIQ Solutions Announces a New Category III CPT Code for Determining Heterogeneity of Change Across All Lesions for Advanced Metastatic Cancer Used with TRAQinform IQ Technology
Published on
AIQ Solutions Announces a New Category III CPT Code for Determining Heterogeneity of Change Across All Lesions for Advanced Metastatic Cancer Used with TRAQinform IQ Technology CPT code is a major milestone to scale late-stage cancer analysis technology across the healthcare system MADISON, Wis., March 3, 2026 /PRNewswire/ — AIQ Solutions today announced a significant…
-
Nuclide Therapeutics secures a £5 million investment from Marathon Beteiligungs-AG
Published on
Nuclide Therapeutics secures a £5 million investment from Marathon Beteiligungs-AG Nuclide Therapeutics Ltd, a pioneering biotech company and King’s College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers, is pleased to announce the successful closure of a £5 million milestone-based first investment round, funded by Marathon Beteiligungs AG. Nuclide received the largest pre-money…
-
WMT AG receives financing with participation from L-Bank’s “InnoGrowth BW” program
Published on
Marathon Beteiligungs AG is the lead investor, CARMA Funds also participates in €3.67 million round. Heidelberg-based WMT AG today announced the completion of an equity financing round totaling €3.63 million. The lead investor, which was able to significantly expand its investment with the InnoGrowth BW program of L-Bank, is Dresden-based Marathon Beteiligungs AG, which is…
